ACADIA Pharmaceuticals Inc. Aktie News

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report fourth quarter and full year 2025 financial results on Wednesday, February 25, 2026, after the close of the U.S. financial markets. Acadia's management team will also host a conference call and webcast on February 25, 2026, at 4:30 p.m. Eastern Time. The conference call will be available o...

Class A shares of the Alger Weatherbie Specialized Growth Fund outperformed the Russell 2500 Growth Index during the fourth quarter of 2025. Natera, Inc., ACADIA Pharmaceuticals Inc., and Glaukos Corp were among the top contributors to performance. FirstService Corp, AAR CORP., and Kratos Defense & Security Solutions, Inc. were among the top detractors from performance.

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Company was informed by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) of a negative trend vote on its Marketing Authorization Application (MAA) for trofinetide for the treatment of Rett syndrome, following its recent CHMP oral explanation. Subject to...

ACADIA Pharmaceuticals Inc. (ACAD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced multiple business updates and progress on the Company's neurological and rare disease drug candidates, which will be discussed today during a presentation by Catherine Owen Adams, Chief Executive Officer, at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. “2026 marks a pivotal year for...

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Catherine Owen Adams, Chief Executive Officer will represent the company in a session scheduled on Tuesday, January 13, 2026, at 9:45 a.m. Pacific Time / 12:45 p.m. Eastern Time. A live webcast of Acadia's presenta...

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Food and Drug Administration (FDA) has approved DAYBUE® STIX (trofinetide) for oral solution, a dye- and preservative-free powder formulation of trofinetide for the treatment of Rett syndrome in adult and pediatric patients two years of age and older. The new formulation is expected to deliver t...

Acadia Pharmaceuticals Inc. is rated Buy for its steady NUPLAZID/DAYBUE franchises and pipeline-driven upside potential. NUPLAZID's patent protection now extends to 2030, supporting >10% Y/Y revenue growth and providing a stable revenue base. DAYBUE missed launch expectations but remains a durable rare-disease asset; ex-U.S. growth is likely to be modest.